NCT03682692View on ClinicalTrials.gov

ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)

PHASE4CompletedINTERVENTIONAL

Enrollment

560

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

March 31, 2022

Conditions

Hypertension

Interventions

DRUG

ACEI/CCB

benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination

DRUG

ACEI/DIU

benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination

Trial Locations (1)

200025

Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors

lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT03682692 - ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD) | Biotech Hunter | Biotech Hunter